{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:08:43Z","timestamp":1789074523248,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacc.2026.02.5123","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:34:07Z","timestamp":1776263647000},"page":"2963-2977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3697-1477","authenticated-orcid":false,"given":"Fan","family":"Bu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruopeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ostropolets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3197-2657","authenticated-orcid":false,"given":"Arya","family":"Aminorroaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5664-4126","authenticated-orcid":false,"given":"Lovedeep Singh","family":"Dhingra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Falconer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-2404","authenticated-orcid":false,"given":"Jason C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1802-1777","authenticated-orcid":false,"given":"Chungsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2320-0470","authenticated-orcid":false,"given":"Wallis C.Y.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth K.C.","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Minty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis","family":"Thangraraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mui","family":"Van Zandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hripcsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Suchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10397","key":"10.1016\/j.jacc.2026.02.5123_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jacc.2026.02.5123_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41569-023-00877-z","article-title":"Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention","volume":"20","author":"Wong","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"10.1016\/j.jacc.2026.02.5123_bib3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"25","key":"10.1016\/j.jacc.2026.02.5123_bib4","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","article-title":"Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease: results from the LEADER trial","volume":"138","author":"Mann","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacc.2026.02.5123_bib5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"issue":"22","key":"10.1016\/j.jacc.2026.02.5123_bib6","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacc.2026.02.5123_bib7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program","volume":"138","author":"R\u00e5dholm","year":"2018","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.jacc.2026.02.5123_bib8","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.jacc.2026.02.5123_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jacc.2026.02.5123_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jacc.2026.02.5123_bib11","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1007\/s00125-021-05529-w","article-title":"The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"issue":"17","key":"10.1016\/j.jacc.2026.02.5123_bib12","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.02.5123_bib13","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jacc.2026.02.5123_bib14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.dsx.2020.04.051","article-title":"Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"9","key":"10.1016\/j.jacc.2026.02.5123_bib15","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1177\/00033197231183229","article-title":"GLP-1 receptor agonists and SGLT-2 inhibitors in patients with versus without cardiovascular disease: a systematic review, meta-analysis, and trial sequential analysis","volume":"75","author":"Kilickap","year":"2024","journal-title":"Angiology"},{"issue":"4","key":"10.1016\/j.jacc.2026.02.5123_bib16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/M20-0864","article-title":"Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis","volume":"173","author":"Tsapas","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jacc.2026.02.5123_bib17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12933-020-01197-z","article-title":"Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis","volume":"20","author":"Yamada","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.jacc.2026.02.5123_bib18","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12933-023-01877-6","article-title":"Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study","volume":"22","author":"Sohn","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.jacc.2026.02.5123_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacc.2026.02.5123_bib20","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2337\/dc20-1890","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases","volume":"43","author":"Xie","year":"2020","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.jacc.2026.02.5123_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003991","article-title":"Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes","volume":"12","author":"Franchi","year":"2024","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jacc.2026.02.5123_bib22","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.mayocp.2023.01.023","article-title":"SGLT2 inhibitors are associated with reduced cardiovascular disease in patients with type 2 diabetes: an analysis of real-world data","volume":"98","author":"Wang","year":"2023","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.jacc.2026.02.5123_bib23","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.jacc.2026.02.5123_bib24","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jacc.2024.05.069","article-title":"Comparative effectiveness of second-line antihyperglycemic agents for cardiovascular outcomes","volume":"84","author":"Khera","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.02.5123_bib25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijcard.2022.01.042","article-title":"Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice","volume":"352","author":"Fu","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2026.02.5123_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-020-01049-w","article-title":"Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice","volume":"19","author":"Longato","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"23","key":"10.1016\/j.jacc.2026.02.5123_bib27","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacc.2026.02.5123_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jacc.2026.02.5123_bib29","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacc.2026.02.5123_bib30","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.jacc.2026.02.5123_bib31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2026.02.5123_bib32","first-page":"S207","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes\u20142025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.jacc.2026.02.5123_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001451","article-title":"Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life","volume":"8","author":"Longato","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jacc.2026.02.5123_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103162","article-title":"Comparative cardiovascular effectiveness of newer glucose-lowering drugs in elderly with type 2 diabetes: a target trial emulation cohort study","volume":"82","author":"Kosjerina","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.jacc.2026.02.5123_bib35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ehjcvp\/pvab053","article-title":"Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.jacc.2026.02.5123_bib36","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12933-023-01911-7","article-title":"Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study","volume":"22","author":"Lim","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.jacc.2026.02.5123_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2023-000651","article-title":"Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM","volume":"2","author":"Khera","year":"2023","journal-title":"BMJ Med"},{"key":"10.1016\/j.jacc.2026.02.5123_bib38","first-page":"574","article-title":"Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers","volume":"216","author":"Hripcsak","year":"2015","journal-title":"Stud Health Technol Inf"},{"issue":"6","key":"10.1016\/j.jacc.2026.02.5123_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057977","article-title":"Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies","volume":"12","author":"Khera","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.jacc.2026.02.5123_bib40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/amiajnl-2011-000376","article-title":"Validation of a common data model for active safety surveillance research","volume":"19","author":"Overhage","year":"2012","journal-title":"J Am Med Inf Assoc"},{"issue":"12","key":"10.1016\/j.jacc.2026.02.5123_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012413","article-title":"Automatic identification of type 2 diabetes, hypertension, ischaemic heart disease, heart failure and their levels of severity from Italian general practitioners\u2019 electronic medical records: a validation study","volume":"6","author":"Gini","year":"2016","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.jacc.2026.02.5123_bib42","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/ije\/dyy120","article-title":"Evaluating large-scale propensity score performance through real-world and synthetic data experiments","volume":"47","author":"Tian","year":"2018","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jacc.2026.02.5123_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2022.104204","article-title":"Adjusting for indirectly measured confounding using large-scale propensity score","volume":"134","author":"Zhang","year":"2022","journal-title":"J Biomed Inf"},{"issue":"2","key":"10.1016\/j.jacc.2026.02.5123_bib44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/sim.5925","article-title":"Interpreting observational studies: why empirical calibration is needed to correct p-values","volume":"33","author":"Schuemie","year":"2014","journal-title":"Stat Med"},{"issue":"22","key":"10.1016\/j.jacc.2026.02.5123_bib45","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1002\/sim.6977","article-title":"Robust empirical calibration of p-values using observational data","volume":"35","author":"Schuemie","year":"2016","journal-title":"Stat Med"},{"issue":"2128","key":"10.1016\/j.jacc.2026.02.5123_bib46","article-title":"Improving reproducibility by using high-throughput observational studies with empirical calibration","volume":"376","author":"Schuemie","year":"2018","journal-title":"Philos Trans Math Phys Eng Sci"},{"key":"10.1016\/j.jacc.2026.02.5123_bib47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jbi.2016.12.005","article-title":"Accuracy of an automated knowledge base for identifying drug adverse reactions","volume":"66","author":"Voss","year":"2017","journal-title":"J Biomed Inf"},{"issue":"11","key":"10.1016\/j.jacc.2026.02.5123_bib48","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1073\/pnas.1708282114","article-title":"Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data","volume":"115","author":"Schuemie","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.jacc.2026.02.5123_bib49","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/jamia\/ocae317","article-title":"Objective study validity diagnostics: a framework requiring pre-specified, empirical verification to increase trust in the reliability of real-world evidence","volume":"32","author":"Conover","year":"2025","journal-title":"J Am Med Inf Assoc"},{"issue":"1","key":"10.1016\/j.jacc.2026.02.5123_bib50","article-title":"How confident are we about observational findings in healthcare: a benchmark study","volume":"2","author":"Schuemie","year":"2020","journal-title":"Harv Data Sci Rev"},{"issue":"11","key":"10.1016\/j.jacc.2026.02.5123_bib51","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/pds.2188","article-title":"Measuring balance and model selection in propensity score methods","volume":"20","author":"Belitser","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.jacc.2026.02.5123_bib52","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/atm.2018.12.10","article-title":"Balance diagnostics after propensity score matching","volume":"7","author":"Zhang","year":"2019","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.jacc.2026.02.5123_bib53","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/aje\/126.2.356","article-title":"A simple estimator of minimum detectable relative risk, sample size, or power in cohort studies","volume":"126","author":"Armstrong","year":"1987","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.jacc.2026.02.5123_bib54","first-page":"185","article-title":"Formulae for sample size, power and minimum detectable relative risk in medical studies","volume":"41","author":"Woodward","year":"1992","journal-title":"J R Stat Soc Ser Stat"},{"issue":"3","key":"10.1016\/j.jacc.2026.02.5123_bib55","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jacc.2026.02.5123_bib57","first-page":"966","article-title":"Health-Analytics Data to Evidence Suite (HADES): open-source software for observational research","volume":"310","author":"Schuemie","year":"2024","journal-title":"Stud Health Technol Inf"},{"issue":"16","key":"10.1016\/j.jacc.2026.02.5123_bib59","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jacc.2026.02.5123_bib60","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacc.2026.02.5123_bib61","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jacc.2026.02.5123_bib62","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacc.2026.02.5123_bib63","doi-asserted-by":"crossref","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 inhibitors in heart failure: a review of current evidence","volume":"5","author":"Talha","year":"2023","journal-title":"Int J Heart Fail"},{"key":"10.1016\/j.jacc.2026.02.5123_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-077097","article-title":"Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data","volume":"385","author":"Bidulka","year":"2024","journal-title":"BMJ"},{"issue":"30","key":"10.1016\/j.jacc.2026.02.5123_bib65","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026431","article-title":"Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients","volume":"100","author":"Duan","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.jacc.2026.02.5123_bib66","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-022-01474-z","article-title":"The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs","volume":"21","author":"Giugliano","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.jacc.2026.02.5123_bib67","first-page":"199","article-title":"Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis","volume":"71","author":"Sabouret","year":"2022","journal-title":"Minerva Cardiol Angiol"},{"issue":"3","key":"10.1016\/j.jacc.2026.02.5123_bib68","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2337\/dc20-1464","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults","volume":"44","author":"Patorno","year":"2021","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.jacc.2026.02.5123_bib69","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.clinthera.2016.11.002","article-title":"SGLT2 Inhibitor\u2013associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis","volume":"38","author":"Goldenberg","year":"2016","journal-title":"Clin Ther"},{"issue":"16","key":"10.1016\/j.jacc.2026.02.5123_bib70","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.jacc.2024.01.040","article-title":"Genitourinary tract infections in patients taking SGLT2 inhibitors: JACC review topic of the week","volume":"83","author":"Kittipibul","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacc.2026.02.5123_bib71","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.jacc.2026.02.5123_bib72","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.jacc.2026.02.5123_bib73","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1007\/s00125-025-06439-x","article-title":"Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes","volume":"68","author":"Lim","year":"2025","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.jacc.2026.02.5123_bib74","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/dom.70269","article-title":"One-year usage patterns of SGLT-2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes in a real-world population","volume":"28","author":"Donnelly","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.jacc.2026.02.5123_bib75","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726057244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726057244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:43:09Z","timestamp":1780411389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726057244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":73,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0735109726057244"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.02.5123","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Cardiovascular Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.02.5123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}